World Pharmaceutical Frontiers

World Pharmaceutical Frontiers serves as the top resource for leading pharmaceutical firms, offering trustworthy and precise insights into new trends and innovative technologies. This valuable information aids companies in making important business choices.

International

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#1699451

United States

#592785

Health/Biotechnology and Pharmaceuticals

#512

Traffic sources

Monthly visitors

Articles

Allay Therapeutics secures $57.5m funding to advance ATX101

3 weeks ago | worldpharmaceuticals.net | Vidya Sagar Maddela

US-based biotechnology company Allay Therapeutics has secured $57.5m in a Series D financing round, co-led by Lightstone Ventures and ClavystBio, to advance ATX101. Other participants in the funding round include existing investors NEA and Arboretum Ventures and new investors including IPD Capital and EDBI. The financing will support Allay’s Phase 2b registration trial of ATX101, targeting post-surgical pain relief following total knee replacement surgery.
Sydnexis gets EC approval for SYD-101 to treat paediatric myopia

3 weeks ago | worldpharmaceuticals.net | Vidya Sagar Maddela

US-based biopharmaceutical company Sydnexis has received the European Commission (EC) marketing authorisation for SYD-101, a key development in paediatric eye care. SYD-101 is the company’s exclusive low-dose atropine formulation, intended for slowing the progression of paediatric myopia. It is the first and only approved treatment option for myopia progression in EU countries.
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan

3 weeks ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence’s artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025.
Alvotech and Dr. Reddy's to co-develop biosimilar to Keytruda

3 weeks ago | worldpharmaceuticals.net | Swagath Bandhakavi

Alvotech has formed a collaboration with India-based Dr. Reddy’s Laboratories to co-develop, produce, and market a biosimilar version of Keytruda (pembrolizumab) for international markets. Listed on Nasdaq, Alvotech is a biotechnology firm focused on biosimilar medicines. Dr. Reddy’s Laboratories is a pharmaceutical company based in India. The partnership aims to leverage the strengths of both companies in biosimilars, thereby accelerating development processes and expanding global distribution.
Vividion acquires WRN inhibitor to enhance oncology pipeline

3 weeks ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Vividion Therapeutics, a subsidiary of Bayer, has strengthened its oncology development pipeline with the acquisition of exclusive global rights to VVD-214 from Roche. VVD-214 is a clinical-stage Werner helicase (WRN) inhibitor that targets cancers with microsatellite instability (MSI), such as colorectal, endometrial, ovarian, and gastric cancers.
Molecular Health, Axxam partner to advance drug target discovery

3 weeks ago | worldpharmaceuticals.net | Vidya Sagar Maddela

German biotechnology company Molecular Health and Italy-based Axxam have entered a strategic partnership to enhance the discovery of advanced drug targets. The collaboration aims to provide biopharmaceutical companies with precise, clinically driven solutions. It integrates Molecular Health’s AI-driven Dataome platform with Axxam’s DiscoveryMAXX process to advance the identification and validation of novel therapeutic targets.
Acerand Therapeutics begins Phase 1 trial of ACE-232 in mCRPC

3 weeks ago | worldpharmaceuticals.net | Swagath Bandhakavi

Acerand Therapeutics has commenced its first human clinical trial of ACE-232, an oral CYP11A1 inhibitor designed for patients with metastatic castration-resistant prostate cancer (mCRPC). The first patient has been dosed as part of this early-stage study, which is expected to feature 67 patients. The Phase I trial, identified as NCT06801236, is being held across multiple centres in both the US and China.
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma

3 weeks ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Oncovita, a biotechnology company developing innovative virus-based immunotherapies for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, MVdeltaC, for the treatment of pleural mesothelioma—a rare and aggressive cancer with high unmet medical need and limited therapeutic options.
Takeda gets EC approval for Adcetris to treat Hodgkin lymphoma

3 weeks ago | worldpharmaceuticals.net | Vidya Sagar Maddela

Japanese pharmaceutical company Takeda has secured European Commission (EC) approval for Adcetris (brentuximab vedotin) in combination with chemotherapy to treat Hodgkin lymphoma in adults. The chemotherapy includes etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (ECADD). Adcetris is an antibody-drug conjugate (ADC) that targets CD30-positive tumour cells.
World Pharmaceutical Frontiers

3 weeks ago | worldpharmaceuticals.net | Vidya Sagar Maddela

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive crises, which may occur via inflammation, in sickle cell disease. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US.